Case Study Four: How do you manage toxicities in patients receiving PARP inhibitors for maintenance treatment of ovarian cancer?
Dr. Michael Birrer introduces a case study involving a patient receiving PARP inhibitor maintenance therapy and discusses key considerations in managing risks and side effects with his colleagues, Drs. David Doo and Brian Slomovitz.
Explore the case further by viewing the case summary slides or by watching the panel discussion video—or download the slides for later review offline.
Key Discussion Questions
What are the major safety considerations when prescribing a PARP inhibitor as maintenance treatment to a patient with ovarian cancer?
How do you determine what is a favorable risk/benefit ratio when deciding to treat with a PARP inhibitor in the maintenance setting?